TY - JOUR
T1 - Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia
T2 - Is It Better Than Day-90 Value—A Multicenter Study From South India
AU - Karpurmath, Shashidhar V.
AU - Seshachalam, Arun
AU - Selvaraj, Kalaiselvi
AU - Rajamani, Priyadarshini
AU - kumar, Satish
AU - Reddy, Neelesh
AU - Malipatil, Baswant
AU - Sirigeri, Roopa
AU - Prasad, Krishna
AU - Reddy, Krishna
AU - Danthala, Madhav
AU - Udupa, Karthik S.
AU - Nandennavar, Manjunath
AU - Murugesan, Janarthinakani
AU - Patil, C. N.
AU - Anoop, Parameswaran
AU - Jacob, Roshan Koshy
AU - Kalashetty, Mallikarjun
AU - Rathnam, Krishnakumar
AU - Ganapathy, Ramanan
PY - 2020/5/1
Y1 - 2020/5/1
N2 - We found that the rate of decline of BCR-ABL1 (breakpoint cluster region-Abelson 1) is a better predictor of the molecular response in patients with chronic myeloid leukemia than the single 90-day value. The present retrospective cohort study of 90 patients is the first study in the Indian context comparing the rate of decline of BCR-ABLl against the single 90-day value.
AB - We found that the rate of decline of BCR-ABL1 (breakpoint cluster region-Abelson 1) is a better predictor of the molecular response in patients with chronic myeloid leukemia than the single 90-day value. The present retrospective cohort study of 90 patients is the first study in the Indian context comparing the rate of decline of BCR-ABLl against the single 90-day value.
UR - http://www.scopus.com/inward/record.url?scp=85081005216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081005216&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2019.09.606
DO - 10.1016/j.clml.2019.09.606
M3 - Article
AN - SCOPUS:85081005216
SN - 2152-2650
JO - Clinical Lymphoma
JF - Clinical Lymphoma
ER -
